Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc K Walton

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders : Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases|October 25, 2002
Endpoint considerations for clinical trialsMarc K Walton
Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders : Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases|October 30, 2004
Use of surrogate markersMarc K Walton
Journal of Biopharmaceutical Statistics|February 26, 2010
Addressing and advancing the problem of missing dataMarc K Walton
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 25, 2012
Evaluating cognitive outcome measures for MS clinical trials: what is a clinically meaningful change?Ralph H B Benedict, Marc K Walton
Expert Opinion on Medical Diagnostics|March 15, 2013
Qualifying biomarkers for use in drug development: a US Food and Drug Administration overviewJanet Woodcock, Shaavhree Buckman, Federico Goodsaid, et al.
Therapeutic Innovation & Regulatory Science|May 27, 2023
Defining Clinical Trial Estimands: A Practical Guide for Study Teams with Examples Based on a Psychiatric DisorderElena Polverejan, Michael O'Kelly, Nanco Hefting, et al.
Journal of the American Academy of Dermatology|August 23, 2005
Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic casesTimothy R Coté, Aparna K Mohan, Jacquelyn A Polder, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 28, 2015
Clinical Outcome Assessments: Conceptual Foundation-Report of the ISPOR Clinical Outcomes Assessment - Emerging Good Practices for Outcomes Research Task ForceMarc K Walton, John H Powers, Jeremy Hobart, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|February 19, 2017
Clinician-Reported Outcome Assessments of Treatment Benefit: Report of the ISPOR Clinical Outcome Assessment Emerging Good Practices Task ForceJohn H Powers, Donald L Patrick, Marc K Walton, et al.
Therapeutic Innovation & Regulatory Science|September 22, 2018
DIA's Adaptive Design Scientific Working Group (ADSWG): Best Practices Case Studies for "Less Well-understood" Adaptive DesignsEva Miller, Paul Gallo, Weili He, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders : Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases|October 25, 2002
Endpoint considerations for clinical trialsMarc K Walton
Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders : Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases|October 30, 2004
Use of surrogate markersMarc K Walton
Journal of Biopharmaceutical Statistics|February 26, 2010
Addressing and advancing the problem of missing dataMarc K Walton
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 25, 2012
Evaluating cognitive outcome measures for MS clinical trials: what is a clinically meaningful change?Ralph H B Benedict, Marc K Walton
Expert Opinion on Medical Diagnostics|March 15, 2013
Qualifying biomarkers for use in drug development: a US Food and Drug Administration overviewJanet Woodcock, Shaavhree Buckman, Federico Goodsaid, et al.
Therapeutic Innovation & Regulatory Science|May 27, 2023
Defining Clinical Trial Estimands: A Practical Guide for Study Teams with Examples Based on a Psychiatric DisorderElena Polverejan, Michael O'Kelly, Nanco Hefting, et al.
Journal of the American Academy of Dermatology|August 23, 2005
Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic casesTimothy R Coté, Aparna K Mohan, Jacquelyn A Polder, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 28, 2015
Clinical Outcome Assessments: Conceptual Foundation-Report of the ISPOR Clinical Outcomes Assessment - Emerging Good Practices for Outcomes Research Task ForceMarc K Walton, John H Powers, Jeremy Hobart, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|February 19, 2017
Clinician-Reported Outcome Assessments of Treatment Benefit: Report of the ISPOR Clinical Outcome Assessment Emerging Good Practices Task ForceJohn H Powers, Donald L Patrick, Marc K Walton, et al.
Therapeutic Innovation & Regulatory Science|September 22, 2018
DIA's Adaptive Design Scientific Working Group (ADSWG): Best Practices Case Studies for "Less Well-understood" Adaptive DesignsEva Miller, Paul Gallo, Weili He, et al.
Pageof 2